FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083600248> ?p ?o ?g. }

• W2083600248 endingPage "419" @default.
• W2083600248 startingPage "415" @default.
• W2083600248 abstract "In Brief Purpose: Steroids are often used as medical therapy for active thyroid eye disease (TED). While high-dose steroids have been shown to be effective in reducing the severity of TED symptoms, the side effects of steroids can be severe. As the pathogenesis of TED is thought to involve the upregulation of proinflammatory cytokines, including tumor necrosis factor-α (TNF-α), it has been postulated that anti-TNF agents may be used as steroid-sparing agents in the treatment of TED. This retrospective study was conducted to examine the efficacy of adalimumab, a subcutaneously administered TNF-α antagonist, in treating the inflammatory symptoms of active TED. Methods: All patients in the inflammatory phase of TED who were treated with adalimumab at the Jules Stein Eye Institute over a 2-year period were reviewed. Data concerning visual acuity, optic nerve function, extraocular motility restriction, binocular visual fields, and proptosis were extracted from patient charts. Clinical photographs from baseline and 3-month follow-up visits were reviewed by masked orbital specialists. Each photograph was graded on the severity of conjunctival injection, chemosis, eyelid erythema, and eyelid edema on a scale from 1 to 4. An inflammatory score was calculated as the sum of these 4 elements. Groups were compared using paired t tests. Results: Six of 10 patients showed a decrease in inflammatory score while on adalimumab, whereas 3 showed an increase and 1 stayed the same. One patient experienced a significant complication (hospital admission for sepsis). Eight patients received concomitant tapering steroids during the first 6 weeks of therapy as the adalimumab reached maximum efficacy. When data from all 10 subjects were analyzed together, there was no significant change in inflammatory index after 3 months of treatment with adalimumab. However, when the 5 patients with a high baseline inflammatory index (>4) were considered separately, there was a significant improvement (mean decrease of 5.2 ± 2.7; p < 0.01) after adalimumab treatment. Four of 5 patients also reported a subjective improvement in symptoms while on adalimumab. Conclusions: This study suggests that adalimumab may have a role in the treatment of active TED with prominent inflammatory symptoms. The use of adalimumab and other immunosuppressive agents in the treatment of TED may help to mitigate some of the metabolic and psychiatric side effects of pulsed steroid treatment. A future randomized controlled study will be necessary to determine the efficacy of adalimumab as a primary therapy for TED. In this retrospective study, patients with active-stage thyroid eye disease with inflammatory signs tended to have a reduction in overall inflammation with adalimumab. Without a control group, it is not possible to determine the true effect of this medication’s over natural history, but adalimumab demonstrates some promise as a steroid-sparing agent for thyroid eye disease." @default.
• W2083600248 created "2016-06-24" @default.
• W2083600248 creator A5023317276 @default.
• W2083600248 creator A5060575717 @default.
• W2083600248 creator A5061972197 @default.
• W2083600248 creator A5072803709 @default.
• W2083600248 creator A5083228413 @default.
• W2083600248 date "2014-09-01" @default.
• W2083600248 modified "2023-09-27" @default.
• W2083600248 title "Adalimumab as Steroid-Sparing Treatment of Inflammatory-Stage Thyroid Eye Disease" @default.
• W2083600248 cites W1968416967 @default.
• W2083600248 cites W1979364075 @default.
• W2083600248 cites W2020862624 @default.
• W2083600248 cites W2038106393 @default.
• W2083600248 cites W2052463348 @default.
• W2083600248 cites W2057742899 @default.
• W2083600248 cites W2071435436 @default.
• W2083600248 cites W2092951259 @default.
• W2083600248 cites W2100125044 @default.
• W2083600248 cites W2108552047 @default.
• W2083600248 cites W2122000071 @default.
• W2083600248 cites W2122429559 @default.
• W2083600248 cites W2127696180 @default.
• W2083600248 cites W2152080639 @default.
• W2083600248 cites W2166592840 @default.
• W2083600248 doi "https://doi.org/10.1097/iop.0000000000000211" @default.
• W2083600248 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24978425" @default.
• W2083600248 hasPublicationYear "2014" @default.
• W2083600248 type Work @default.
• W2083600248 sameAs 2083600248 @default.
• W2083600248 citedByCount "59" @default.
• W2083600248 countsByYear W20836002482014 @default.
• W2083600248 countsByYear W20836002482015 @default.
• W2083600248 countsByYear W20836002482016 @default.
• W2083600248 countsByYear W20836002482017 @default.
• W2083600248 countsByYear W20836002482018 @default.
• W2083600248 countsByYear W20836002482019 @default.
• W2083600248 countsByYear W20836002482020 @default.
• W2083600248 countsByYear W20836002482021 @default.
• W2083600248 countsByYear W20836002482022 @default.
• W2083600248 countsByYear W20836002482023 @default.
• W2083600248 crossrefType "journal-article" @default.
• W2083600248 hasAuthorship W2083600248A5023317276 @default.
• W2083600248 hasAuthorship W2083600248A5060575717 @default.
• W2083600248 hasAuthorship W2083600248A5061972197 @default.
• W2083600248 hasAuthorship W2083600248A5072803709 @default.
• W2083600248 hasAuthorship W2083600248A5083228413 @default.
• W2083600248 hasConcept C126322002 @default.
• W2083600248 hasConcept C141071460 @default.
• W2083600248 hasConcept C2776652619 @default.
• W2083600248 hasConcept C2777138892 @default.
• W2083600248 hasConcept C2778257484 @default.
• W2083600248 hasConcept C2779134260 @default.
• W2083600248 hasConcept C2779714575 @default.
• W2083600248 hasConcept C2780132546 @default.
• W2083600248 hasConcept C2781302119 @default.
• W2083600248 hasConcept C526584372 @default.
• W2083600248 hasConcept C71924100 @default.
• W2083600248 hasConceptScore W2083600248C126322002 @default.
• W2083600248 hasConceptScore W2083600248C141071460 @default.
• W2083600248 hasConceptScore W2083600248C2776652619 @default.
• W2083600248 hasConceptScore W2083600248C2777138892 @default.
• W2083600248 hasConceptScore W2083600248C2778257484 @default.
• W2083600248 hasConceptScore W2083600248C2779134260 @default.
• W2083600248 hasConceptScore W2083600248C2779714575 @default.
• W2083600248 hasConceptScore W2083600248C2780132546 @default.
• W2083600248 hasConceptScore W2083600248C2781302119 @default.
• W2083600248 hasConceptScore W2083600248C526584372 @default.
• W2083600248 hasConceptScore W2083600248C71924100 @default.
• W2083600248 hasIssue "5" @default.
• W2083600248 hasLocation W20836002481 @default.
• W2083600248 hasLocation W20836002482 @default.
• W2083600248 hasOpenAccess W2083600248 @default.
• W2083600248 hasPrimaryLocation W20836002481 @default.
• W2083600248 hasRelatedWork W1793302197 @default.
• W2083600248 hasRelatedWork W2028253275 @default.
• W2083600248 hasRelatedWork W2034536484 @default.
• W2083600248 hasRelatedWork W2096634953 @default.
• W2083600248 hasRelatedWork W2805758791 @default.
• W2083600248 hasRelatedWork W2808894190 @default.
• W2083600248 hasRelatedWork W2893592052 @default.
• W2083600248 hasRelatedWork W3157290455 @default.
• W2083600248 hasRelatedWork W4318922495 @default.
• W2083600248 hasRelatedWork W2404010147 @default.
• W2083600248 hasVolume "30" @default.
• W2083600248 isParatext "false" @default.
• W2083600248 isRetracted "false" @default.
• W2083600248 magId "2083600248" @default.
• W2083600248 workType "article" @default.